The firm's financial position is characterized by a $80.8 million accumulated deficit as of 2026Q1, leaving the company with minimal tangible assets beyond its $10.2 million cash position.
| Total Current Assets | 10.91M | 12.71M | 3.36M | 15.46M | 1.45M | 4.73M | 9.48M | 8.65M |
| Cash & Short-Term Investments | 10.24M | 11.92M | 2.59M | 14.78M | 1.31M | 4.54M | 9.32M | 8.39M |
| Cash Only | 10.24M | 11.92M | 2.59M | 8.56M | 1.31M | 4.54M | 9.32M | 3.83M |
| Short-Term Investments | 0 | 0 | 0 | 6.22M | 0 | 0 | 0 | 4.56M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 62.3K | 51.26K | 48.52K | 33.63K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 661K | 0 | 0 | 6K | 13.7K | 69.28K | 46.17K | 166.47K |
| Total Non-Current Assets | 1.39M | 1.39M | 1.42M | 1.83M | 306K | 485.86K | 671.94K | 357.11K |
| Property, Plant & Equipment | 89K | 96K | 122K | 147K | 139K | 318.13K | 490.24K | 252.67K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75K |
| Other Non-Current Assets | 1.3M | 1.3M | 1.3M | 1.68M | 167K | 167.74K | 181.7K | 29.44K |
| Total Assets | 12.29M | 14.1M | 4.78M | 17.3M | 1.76M | 5.22M | 10.15M | 9.01M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Asset Growth % | 530.92% | 194.81% | -72.34% | 884.35% | -66.32% | -48.61% | 12.7% | - |
| Total Current Liabilities | 2.24M | 2.15M | 1.75M | 3.96M | 6.82M | 3.72M | 1.35M | 1.13M |
| Accounts Payable | 636K | 583K | 1.22M | 3.05M | 603K | 172.51K | 222.71K | 393.96K |
| Days Payables Outstanding | 53.39K | 8.18K | - | 7.57K | - | - | - | - |
| Short-Term Debt | 32K | 31K | 0 | 0 | 4.35M | 2.02M | 0 | 117.19K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.57M | 1.53M | 56K | 499K | 0 | 0 | 0 | 6.52K |
| Current Ratio | 4.86x | 5.92x | 1.92x | 3.91x | 0.21x | 1.27x | 7.04x | 7.67x |
| Quick Ratio | 4.86x | 5.92x | 1.92x | 3.91x | 0.21x | 1.27x | 7.04x | 7.67x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 70K | 79K | 110K | 174K | 10.04M | 10.18M | 10.36M | 179.08K |
| Long-Term Debt | 70K | 79K | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 95K | 0 | 110K | 138K | 0 | 143.57K | 326.25K | 143.08K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 36K | 10.04M | 10.04M | 10.04M | 36K |
| Total Liabilities | 2.31M | 2.23M | 1.86M | 4.13M | 16.86M | 13.9M | 11.71M | 1.31M |
| Total Debt | 102K | 110K | 138K | 158K | 4.49M | 2.34M | 497.48K | 260.27K |
| Net Debt | -10.14M | -11.81M | -2.45M | -8.4M | 3.18M | -2.2M | -8.82M | -3.57M |
| Debt / Equity | 0.01x | 0.01x | 0.05x | 0.01x | - | - | - | 0.03x |
| Debt / EBITDA | -0.01x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.21x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -33.55x | -91.71x | -469.87x | - | - |
| Total Equity | 9.98M | 11.88M | 2.92M | 13.16M | -15.1M | -8.68M | -1.56M | 7.7M |
| Equity Growth % | 3295.45% | 306.99% | -77.83% | 187.18% | -73.86% | -457.27% | -120.24% | - |
| Book Value per Share | 0.39 | 0.88 | 5.25 | 38.19 | -110.69 | -63.66 | -11.43 | 56.56 |
| Total Shareholders' Equity | 9.98M | 11.88M | 2.92M | 13.16M | -15.1M | -8.68M | -1.56M | 7.7M |
| Common Stock | 0 | 0 | 2K | 1K | 0 | 341 | 682 | 681 |
| Retained Earnings | -80.82M | -78.39M | -66.78M | -50.52M | -38.65M | -31.07M | -23.18M | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -17.3M | 0 | 0 | 0 | -17.15M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical-stage liquidity constraints
As reported in financial statements, the company's total assets have fluctuated significantly, dropping from $17.3 million in 2023Q4 to $12.3 million by 2026Q1, signaling a persistent contraction in the resource base available to support ongoing clinical development and long-term operational stability for the firm.
The downward trend in total assets reflects the ongoing consumption of cash to fund R&D activities without any offsetting commercial revenue. This trajectory suggests that the company is increasingly reliant on external financing to maintain its current clinical trial velocity, which may limit management's ability to pivot or expand research programs if data readouts are delayed.
Based on recent SEC filings, the current ratio has exhibited extreme volatility, ranging from a low of 0.63 in 2025Q1 to a peak of 5.92 in 2025Q4, highlighting a precarious liquidity profile that leaves the company highly sensitive to the timing of clinical trial expenditures.
The wide swings in the current ratio indicate that the firm's liquidity is not managed through a stable cash buffer but rather through episodic capital raises. Investors should monitor whether the current $11.9 million cash position is sufficient to cover upcoming trial milestones, as any deviation from projected burn rates could necessitate immediate and potentially dilutive financing.
According to the company's reported figures, retained earnings have deteriorated to a deficit of $80.8 million as of 2026Q1, illustrating the heavy toll that sustained, non-revenue-generating R&D investment has taken on the firm's total equity base over the past ten quarters.
The persistent growth of the accumulated deficit underscores the binary nature of the business model, where shareholder value is entirely dependent on future clinical success rather than current operational profitability. The erosion of equity suggests that the company is effectively trading its balance sheet strength for the potential of future intellectual property validation.
As indicated by the provided data, the company's asset base is almost entirely composed of cash, with negligible investment in property, plant, or equipment, which suggests that the firm lacks tangible collateral to support traditional debt financing in the event of a capital market downturn.
The absence of significant PPE or other long-term assets confirms the company's status as a pure-play R&D entity, but it also highlights a lack of operational diversification. This structure implies that the firm's valuation is uniquely vulnerable to regulatory or clinical setbacks, as there are no underlying physical assets to provide a floor for the company's enterprise value.
Quick answers to the most common questions about buying INTS stock.
As of 2025, Intensity Therapeutics, Inc. (INTS) had total assets of $14.1M including $12.7M in current assets.
Intensity Therapeutics, Inc. (INTS) carries total debt of $0.1M, offset by $11.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Intensity Therapeutics, Inc. (INTS) has total shareholders' equity (book value) of $11.9M ($0.88 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Intensity Therapeutics, Inc. (INTS) reported a current ratio of 5.92x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.